Literature DB >> 10419545

Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling.

S Chen1, K Wu, D Zhang, M Sherman, R Knox, C S Yang.   

Abstract

The molecular basis of the interaction of DT-diaphorase with a cytotoxic nitrobenzamide CB1954 [5-(aziridin-1-yl)-2, 4-dinitrobenzamide] and five inhibitors was investigated with wild-type DT-diaphorase (human and rat) and five mutants [three rat mutants (rY128D, rG150V, rH194D) and two human mutants (hY155F, hH161Q)]. hY155F and hH161Q were generated to evaluate a hypothesis that Tyr155 and His161 participate in the obligatory two-electron transfer reaction of the enzyme. The catalytic properties of hY155F and hH161Q were compared with a naturally occurring mutant, hP187S. Pro187 to Ser mutation disturbs the structure of the central parallel beta-sheet, resulting in a reduction of the binding affinity of the flavin-adenine dinucleotide prosthetic group. With NADH as the electron donor and menadione as the electron acceptor, the k(cat) values for the wild-type human DT-diaphorase, hY155F, hH161Q, and hP187S were measured as 66 +/- 1, 23 +/- 0, 5 +/- 0 and 8 +/- 2 x 10(3) min(-1), respectively. Because hY155F still has significant catalytic activity, the hydroxyl group on Tyr155 may not be as important as proposed. Interestingly, hY155F was found to be 3. 3 times more active than the human wild-type DT-diaphorase in the reduction of CB1954. Computer modeling based on our results suggests that CB1954 is situated in the active site, with the aziridinyl group pointing toward Tyr155 and the amide group placed near a hydrophobic pocket next to Tyr128. Dicoumarol, Cibacron blue, chrysin, 7,8-dihydroxyflavone, and phenindone are competitive inhibitors of the enzyme with respect to nicotinamide coenzymes. The binding orientations of dicoumarol, flavones, and phenindone in the active site of DT-diaphorase were predicted by results from our inhibitor-binding studies and computer modeling based on published X-ray structures. Our studies generated results that explain why dicoumarol is a potent inhibitor and binds differently from flavones and phenindone in the active site of DT-diaphorase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419545     DOI: 10.1124/mol.56.2.272

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Reaction mechanism of single subunit NADH-ubiquinone oxidoreductase (Ndi1) from Saccharomyces cerevisiae: evidence for a ternary complex mechanism.

Authors:  Yu Yang; Tetsuo Yamashita; Eiko Nakamaru-Ogiso; Takeshi Hashimoto; Masatoshi Murai; Junsuke Igarashi; Hideto Miyoshi; Nozomu Mori; Akemi Matsuno-Yagi; Takao Yagi; Hiroaki Kosaka
Journal:  J Biol Chem       Date:  2011-01-10       Impact factor: 5.157

2.  NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.

Authors:  Seema Singh; Muhammad Zahid; Muhammad Saeed; Nilesh W Gaikwad; Jane L Meza; Ercole L Cavalieri; Eleanor G Rogan; Dhrubajyoti Chakravarti
Journal:  J Steroid Biochem Mol Biol       Date:  2009-07-21       Impact factor: 4.292

3.  Crystal structure of quinone reductase 2 in complex with resveratrol.

Authors:  Leonid Buryanovskyy; Yue Fu; Molly Boyd; Yuliang Ma; Tze-chen Hsieh; Joseph M Wu; Zhongtao Zhang
Journal:  Biochemistry       Date:  2004-09-14       Impact factor: 3.162

4.  P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.

Authors:  Gad Asher; Joseph Lotem; Peter Tsvetkov; Veronica Reiss; Leo Sachs; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

5.  Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.

Authors:  Maria F Mendoza; Nicole M Hollabaugh; Suraj U Hettiarachchi; Robin L McCarley
Journal:  Biochemistry       Date:  2012-09-28       Impact factor: 3.162

Review 6.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Authors:  David Siegel; Chao Yan; David Ross
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 6.100

7.  Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.

Authors:  Pimradasiri Srijiwangsa; Saranyoo Ponnikorn; Kesara Na-Bangchang
Journal:  BMC Pharmacol Toxicol       Date:  2018-06-19       Impact factor: 2.483

8.  Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release.

Authors:  M Faig; M A Bianchet; P Talalay; S Chen; S Winski; D Ross; L M Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 9.  Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch.

Authors:  David Ross; David Siegel
Journal:  Front Physiol       Date:  2017-08-24       Impact factor: 4.566

Review 10.  Roles of NAD(P)H:quinone Oxidoreductase 1 in Diverse Diseases.

Authors:  Wang-Soo Lee; Woojin Ham; Jaetaek Kim
Journal:  Life (Basel)       Date:  2021-11-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.